Valneva (NASDAQ:VALN) Issues Quarterly Earnings Results

Valneva (NASDAQ:VALN) released its quarterly earnings data on Wednesday. The company reported ($0.54) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.32), Zacks reports. Valneva had a negative net margin of 4.35% and a negative return on equity of 3.93%.

Valneva Stock Up 5.7 %

Shares of NASDAQ VALN traded up $0.38 during midday trading on Thursday, reaching $7.11. 10,067 shares of the company’s stock were exchanged, compared to its average volume of 25,915. Valneva has a 52-week low of $3.62 and a 52-week high of $9.50. The stock has a market capitalization of $578.01 million, a PE ratio of -54.57 and a beta of 1.93. The company has a debt-to-equity ratio of 0.70, a quick ratio of 2.25 and a current ratio of 2.78. The business’s fifty day moving average price is $6.24 and its two-hundred day moving average price is $5.60.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “buy” rating and issued a $17.00 price objective on shares of Valneva in a research report on Friday, February 28th.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.